转自：北京日报客户端 寒冷的冬季是心血管疾病的高发季节。阿司匹林这款常用药也成为很多老年人预防心血管疾病的选择。 阿司匹林的主要适应症是什么？适合长期大量服用吗？是否会带来一些副作用？ 中国医学科学院阜外医院心内科医生刘凯告诉记者，阿司匹林的应用历史很长，最初作为解热镇痛和抗 炎药物应用于临床。后来发现它能够抑制血小板聚集，因而具有良好的预防血栓形成的作用。目前已作 为一种标准治疗药物，被广泛应用于冠心病、脑血管病、外周血管狭窄等各种动脉粥样硬化性疾病的治 疗和预防中。 他表示，针对具体患者，仍需在充分评估的基础上给予个体化的策略，例如调整阿司匹林的应用疗程与 剂量，或必要时考虑其他替代药物（例如氯吡格雷、吲哚布芬等），尽可能减少其出血风险。 梅奥诊所说，对于大多数成年人来说，偶尔服用一两片阿司匹林来缓解头痛、身体疼痛或发烧通常是安 全的。但如果身体健康，没有心脏病或中风病史，每日服用阿司匹林的益处并不明显，甚至可能会产生 严重的副作用和并发症，包括：可能增加出血性中风的风险；增加胃肠道出血风险；导致过敏反应等。 来源：新华社 作者: 彭茜 由于胃刺激是阿司匹林常见的副作用，该药物的正确服用方式也很有讲究。北 ...

Core Viewpoint - The company has developed DT678 tablets, a globally innovative drug for anti-platelet aggregation, which is currently in Phase II clinical trials and shows superior efficacy compared to Clopidogrel with fewer side effects [1][3]. Group 1 - DT678 tablets are a co-development between the company and DT Company, which is partially owned by the University of Michigan, with the company holding a 30% stake in DT Company [1][3]. - The company possesses exclusive rights for the development and use of the patented compound in China [1][3]. - Preliminary results from Phase I trials indicate that DT678 has over 20 times the efficacy of Clopidogrel, with advantages such as rapid onset, fewer side effects, and greater stability [3].

Summary of Conference Call Notes Industry Overview - The conference call discusses the upcoming **11th National Drug Centralized Procurement (国采)**, expected to start in **July or August 2025**. The 10th round had extreme results due to a long time span and rule adjustments, leading to potential product registration backlog issues in the 11th round, with intensified competition and possible rule changes to avoid excessive low pricing [1][4][2]. Key Points and Arguments - **11th Batch Procurement Timing**: The 11th batch is likely to be delayed until the second half of the year due to the need for medical institutions to prepare reporting volumes, with only one round expected this year [2]. - **Biological Drug Procurement**: The biological drug procurement led by Anhui is set for execution by the end of **2025**, based on insulin procurement rules, focusing on moderate price reductions and a larger number of selected products [1][5][6]. - **Quality Control Measures**: The National Medical Products Administration (药监局) is responsible for quality control of selected products, while the National Healthcare Security Administration (医保局) has introduced new rules requiring companies to have market volume before gaining market share, ensuring fair competition [7][3]. - **Impact of New Rules on Original Drug Companies**: The new procurement rules favor original drug companies by allowing them to retain some market share even if not selected, and providing hospitals with more autonomy in choosing products [12][3]. - **Price Discrimination Issues**: The centralized procurement has provided a price benchmark, but there have been instances of price discrimination across provinces, leading to a downward spiral in drug prices and potential shortages [18][19]. - **Market Dynamics for Generic Drugs**: The procurement process has increased the penetration of competitive products in grassroots hospitals, while high-priced drugs have significant market expansion potential [11][21]. Additional Important Content - **Alliance Procurement Framework**: The shift to an alliance procurement framework has led to varied approaches among provinces, with some like Hebei being aggressive in pricing, while others like Guangdong and Xinjiang adopt a more balanced approach [8][9]. - **Future Alliance Plans**: Major alliances for procurement include those led by Sichuan, Xinjiang, Guangdong, and Tianjin, with Shanghai and Jiangsu considering joining new projects [9]. - **Impact on Marketing Strategies**: Original drug companies are adjusting their marketing strategies, increasing collaboration with e-commerce channels to enhance drug accessibility and sales [22][24]. - **Medicare Payment Standards**: The establishment of Medicare payment standards is expected to significantly impact drug prices and market dynamics, potentially leading to a unified pricing structure across different regions [13][20]. - **Challenges for Innovative Drugs**: The procurement policies may limit the development of innovative drugs due to low pricing, which could discourage research and development efforts in the pharmaceutical industry [25][26]. This summary encapsulates the critical insights and implications from the conference call regarding the upcoming drug procurement policies and their potential impact on the pharmaceutical industry.

Core Viewpoint - Heng Rui Medicine has signed a $1.97 billion licensing agreement with Merck for its Lp(a) oral small molecule project, HRS-5346, granting Merck exclusive rights for development, production, and commercialization outside Greater China [1][2]. Company Summary - The agreement includes an upfront payment of $200 million from Merck, with potential milestone payments not exceeding $1.77 billion, plus sales royalties based on net sales of HRS-5346 after market launch, totaling at least $1.97 billion for Heng Rui Medicine [1][2]. - HRS-5346 is currently undergoing Phase II clinical trials in China and has the potential to reduce Lp(a) levels in the blood by over 80%, addressing a global patient population of 1.4 billion suffering from cardiovascular diseases linked to elevated Lp(a) [1][2]. - Heng Rui Medicine has been actively pursuing overseas licensing as part of its international expansion strategy, with 13 innovative drugs already licensed abroad [2]. Industry Summary - In 2024, the total upfront payments for overseas licensing in China's biopharmaceutical industry are projected to reach $4.94 billion, surpassing the $3.77 billion in financing for innovative drug research and development in the first year [3]. - Upfront payments provide direct funding for research and development, reducing reliance on equity financing for pharmaceutical companies [3].